Claims for Patent: 9,526,764

Summary for Patent: 9,526,764

Title:	Combination of an insulin and a GLP-1-agonist
Abstract:	The invention relates to a drug comprising at least one insulin and at least one GLP-1 receptor agonist.
Inventor(s):	Werner; Ulrich (Frankfurt am Main, DE), Rotthauser; Barbel (Frankfurt am Main, DE)
Assignee:	SANOFI-AVENTIS DEUTSCHLAND GMBH (Frankfurt am Main, DE)
Application Number:	13/123,835
Patent Claims:	1. A pharmaceutical formulation comprising a combination of: (a) insulin glargine or a pharmaceutically acceptable salt thereof, and (b) desPro.sup.36exendin-4(1-39)-Lys.sub.6-NH.sub.2 (AVE0010) or a pharmaceutically acceptable salt thereof wherein the concentration of insulin glargine is about 100 units/mL, and the concentration of AVE0010 is about 20 .mu.g/ml to about 150 .mu.g/ml. 2. The pharmaceutical formulation of claim 1, wherein the concentration of insulin glargine is about 100 units/mL, and the concentration of AVE0010 is about 25, 33, 40, 66, or 75 .mu.g/mL. 3. The pharmaceutical formulation of claim 2, wherein the concentration of insulin glargine is about 100 units/mL, and the concentration of AVE0010 is about 25 .mu.g/mL. 4. The pharmaceutical formulation of claim 2, wherein the concentration of insulin glargine is about 100 units/mL, and the concentration of AVE0010 is about 33 .mu.g/mL. 5. The pharmaceutical formulation of claim 2, wherein the concentration of insulin glargine is about 100 units/mL, and the concentration of AVE0010 is about 40 .mu.g/mL. 6. The pharmaceutical formulation of claim 2, wherein the concentration of insulin glargine is about 100 units/mL, and the concentration of AVE0010 is about 66 .mu.g/mL. 7. The pharmaceutical formulation of claim 2, wherein the concentration of insulin glargine is about 100 units/mL, and the concentration of AVE0010 is about 75 .mu.g/mL. 8. A pharmaceutical formulation comprising a combination of: (a) insulin glargine or a pharmaceutically acceptable salt thereof, and (b) AVE0010 or a pharmaceutically acceptable salt thereof; wherein the concentration of insulin glargine is about 100 units/mL, and wherein insulin glargine and AVE0010 are present in a ratio of about 1.5 units to about 4 units of insulin glargine to 1 .mu.g of AVE0010. 9. The pharmaceutical formulation of claim 8, wherein insulin glargine and AVE0010 are present in a ratio of about 3 units of insulin glargine to 1 .mu.g of AVE0010. 10. The pharmaceutical formulation of claim 8, wherein insulin glargine and AVE0010 are present in a ratio of about 2 units of insulin glargine to 1 .mu.g of AVE0010. 11. A pharmaceutical formulation comprising a combination of: (a) insulin glargine or a pharmaceutically acceptable salt thereof, and (b) desPro.sup.36exendin-4(1-39)-Lys.sub.6-NH.sub.2 (AVE0010) or a pharmaceutically acceptable salt thereof; wherein the dosage of insulin glargine is between about 5 units and about 100 units, and the dosage of AVE0010 is between about 5 .mu.g and about 2 mg. 12. The pharmaceutical formulation of claim 11, wherein the dosage of insulin glargine is between about 15 units and about 80 units, and the dosage of AVE0010 is between about 10 .mu.g and about 30 .mu.g. 13. The pharmaceutical formulation of claim 11, wherein the dosage of insulin glargine is between about 15 units and about 80 units, and the dosage of AVE0010 is between about 10 .mu.g and about 20 .mu.g. 14. The pharmaceutical formulation of claim 1, 8, or 11, wherein the pharmaceutical formulation is a liquid formulation suitable for parenteral administration. 15. The pharmaceutical formulation of claim 1, 8, or 11, wherein the pharmaceutical formulation is suitable for administration once daily.